Emisphere Technologies Inc. announced an interim paymentfrom Schering-Plough Corp. The money will provide additionalsupport for ongoing studies to determine the feasibility ofEmisphere's proprietary oral drug delivery system toadminister a Schering-Plough product that is otherwiseinjectable.
Emisphere (NASDAQ:EMIS) of Hawthorne, N.Y., said preliminaryresults have been encouraging.
The patented delivery system encapsulates therapeutic agentsin microspheres composed of amino acids that are designed toallow drugs to be absorbed unchanged in the bloodstreamwhile protecting them from the harsh environment of thegastrointestinal tract.
(c) 1997 American Health Consultants. All rights reserved.